John Luk

Dr. John Luk is educated and trained at the University of Hong Kong, Karolinska (Stockholm), and Harvard (Boston). Prior to establishing Arbele, he was an academic professor for 18 years in the US, Hong Kong and Singapore, and a visiting associate professor at Harvard. Through his professorship at leading institutes, he was able to establish strong scientific, clinical, and industrial networks globally. He has published around 200 papers including NEJM, Cell, Nature Medicine, and Nature Genetics. Dr. John identified and patented CDH17 at HKU (Global Licensed to Arbele). In 2011, he found his path to the drug industry at Roche and Janssen Pharmaceutical, to lead drug discovery and development programs in oncology, immunology, and hepatitis.

Companies

• Founder & CEO Arbele (2016)
• Head of Virology & Immunology Drug Discovery Janssen Pharmaceutical R&D (2012 — 2015)
• Senior Director and Head of Oncology Discovery Roche (2011 — 2012)
• Senior PI Cancer Science Institute (2010 — 2011)
• Professor NUHS Dept of Surgery and Dept of Pharmacology (2009 — 2011)
• Associate Professor The University of Hong Kong, Dept of Surgery (1997 — 2009)
• Visiting associate professor of Immunology (Sabbatical) HMS, Brigham and Women's Hospital, Dept of Medicine, Division of Allergy & Immunology (2000 — 2001)
• Assistant Professor of Pediatric Pulmonary Immunology Case Western Reserve University, Dept of Pediatrics, Division of Infectious Diseases (1994 — 1997)
• Merck Academic Fellow Dana-Farber Cancer Institute/CBR, Harvard (1992 — 1994)

Education

• Academic Fellow Harvard Medical School
• Dr.Med.Sc. Karolinska institutet
• B.Sc.(Hon) & M.Ph. The University of Hong Kong
• EMBA The Chinese University of Hong Kong (CUHK) Business School